IBD (Ulcerative Colitis and Crohn’s Disease) Treatment Market
Number of pages: 100 | Report Format: PDF | Published date: March 23, 2023
Historical Years – 2021 | Base Year – 2022 | Forecasted Years – 2023-2031
|
Report Attribute |
Details |
|
Market size value in 2022 |
US$ 23.8 billion |
|
Revenue Forecast in 2031 |
US$ 39.5 billion |
|
CAGR |
5.8% |
|
Base Year for Estimation |
2022 |
|
Forecast Period |
2023-2031 |
|
Historical Year |
2021 |
|
Segments Covered |
Drug Class, Distribution Channel, and Region |
|
Regional Scope |
North America, Europe, Asia Pacific, Latin America, and the Middle East & Africa |
According to the deep-dive market assessment study by Growth Plus Reports, the global IBD (ulcerative colitis and Crohn’s disease) treatment market was valued at US$ 23.8 billion in 2022 and is expected to register a revenue CAGR of 5.8% to reach US$ 39.5 billion by 2031.
IBD (Ulcerative Colitis and Crohn’s Disease) Treatment Market Fundamentals
A series of illnesses known together as inflammatory bowel disease (IBD) results in persistent inflammation in the intestines. This chronic illness can be managed with the aid of treatments. Idiopathic inflammatory bowel disease, which includes ulcerative colitis and Crohn’s disease, is a long-term relapsing and remitting condition. IBD has long been treated with immunosuppressants, aminosalicylates, and corticosteroids. Anti-TNF medications significantly improved clinical results. However, about 50% of patients receiving these medications experience primary failure or loss of response to biologics. In addition, recent developments in IBD therapy have prompted a paradigm change in treatment objectives, moving away from the purpose of symptom-free daily life and toward the target of mucosal repair, which eventually necessitates new therapeutic approaches.
The safety profile of the patients has always been a concern, particularly the elevated risk of infections and malignancies. The years ahead for IBD are promising. New trends in IBD care and novel medications are anticipated to be viable to change the course of the disease and improve therapy and quality of life for people with this disabling condition.
[6575]
IBD (Ulcerative Colitis and Crohn’s Disease) Treatment Market Dynamics
The IBD (ulcerative colitis and Crohn’s disease) treatment market is expected to grow owing to the increasing incidence of ulcerative colitis and Crohn’s disease. According to the Crohn’s & Colitis Foundation of America, more than 1.6 million Americans have ulcerative colitis or Crohn’s disease, and 70,000 new instances of IBD are thought to be diagnosed in the U.S. each year. Numerous lifestyle factors, such as exercise, obesity, stress, sleep deprivation, and smoking, can influence the risk of developing inflammatory bowel illnesses. These lifestyle factors may substantially impact the clinical results and natural history of IBD in patients with existing IBD. Obesity increases the probability of treatment failure and negatively affects the pharmacokinetics of biologic medicines. Independent of disease activity, sleep disturbance is very common in IBD patients. It raises the risk of recurrence and chronic fatigue. Similarly, stress, especially perceived stress as opposed to significant life events, may cause the symptoms to flare up.
Frequent studies have repeatedly demonstrated that smoking is linked to the recurrence of endoscopic, clinical, and surgical Crohn’s disease. Smokers are much more likely than non-smokers to require a second surgery for Crohn’s disease five and ten years after the first procedure. Millions of people live unhealthy lives. A major lifestyle aspect that directly and favorably affects health is diet. In metropolitan civilizations, a poor diet, and its effects, such as obesity, are prevalent health issues. Urban living causes nutrition issues, such as eating fast food and unhealthy foods, which increases the incidence of inflammatory bowel diseases.
The existence of a robust product pipeline and anticipated launches over the course of the projection period are projected to fuel market revenue growth. For instance, phase II clinical studies are underway for AbbVie’s ABBV-154, an anti-TNF GRM ADC anticipated to go on sale in the upcoming years. Similarly, Mirikizumab from Eli Lilly and Company is a big molecule that may be examined for treating IBD and is anticipated to go on sale in 2023. Current treatments concentrate on lowering inflammation, complication risks, and sustained remission. In addition, hospitals and healthcare organizations collaborate closely with pharmaceutical firms to carry out clinical trials and guarantee patient safety. Such measures are anticipated to improve research efforts to create a new IBD treatment.
The market for IBD treatments is gaining traction due to technical improvements. For instance, the top players in the IBD treatment market strongly emphasize using cutting-edge technologies like artificial intelligence (AI) for drug discovery and providing novel medicines for Crohn’s disease and ulcerative colitis. Leading companies and tech innovators are working together to achieve technical advances, so they can use each other’s technology and competencies to develop unique procedures and increase their market positions. For instance, in May 2021, the Israeli tech company CytoReason announced a deal with Ferring Pharmaceuticals to use AI technology to speed up drug development and discover innovative therapies for IBD.
IBD (Ulcerative Colitis and Crohn’s Disease) Treatment Market Ecosystem
The global IBD (ulcerative colitis and Crohn’s disease) treatment market is analyzed from three perspectives: drug class, distribution channel, and region.
IBD (Ulcerative Colitis and Crohn’s Disease) Treatment Market by Drug Class
[85355]
Based on the drug class, the global IBD (ulcerative colitis and Crohn’s disease) treatment market is segmented into TNF inhibitors, JAK inhibitors, aminosalicylates, integrin antagonists, corticosteroids, and others.
The TNF inhibitors segment accounted for the largest revenue share of the global IBD (ulcerative colitis and Crohn’s disease) treatment market in 2022. In terms of sustained clinical remission, sparing of corticosteroids, achieving mucosal healing, and avoiding disease-related comorbidities, using anti-TNF-agents greatly improves the outcomes in IBD patients. The high rate of TNF inhibitor prescriptions for the treatment of IBD and growing consumer knowledge of TNF inhibitors are both responsible for the significant segment revenue share. Humira, Remicade, Simponi, Cimzia, and other biosimilars are important TNF inhibitors for treating inflammatory illnesses. However, the loss of patent protection for TNF inhibitors is projected to impede market expansion in the upcoming years.
The JAK inhibitors market is anticipated to develop quickly during the projected period. The segment’s revenue growth can be due to the rising acceptance of innovative JAK inhibitors and the existence of potent medications in the pipeline that are slated for commercialization in the upcoming years.
IBD (Ulcerative Colitis and Crohn’s Disease) Treatment Market by Distribution Channel
Based on the distribution channel, the global IBD (ulcerative colitis and Crohn’s disease) treatment market is segmented into hospital pharmacies, retail pharmacies, and online pharmacies.
The hospital pharmacies segment accounted for the largest revenue share of the global IBD (ulcerative colitis and Crohn’s disease) treatment market in 2022. Hospital pharmacies have quickly become the favored method of distributing compounded medications. Drug compounding is the act of blending, combining, or changing pharmaceutical materials to produce drugs specifically suited to a patient’s needs. The necessity for medicine compounding in hospital pharmacies has increased due to the availability of competent people who can do such jobs in hospitals. According to new research, people are putting more trust in hospital pharmacies because of their role in care management, such as prescribing drugs, performing health and wellness exams, and offering disease-specific advice. Additionally, almost 8 out of 10 consumers believe that hospital pharmacies are trustworthy sources of general health information outside of medication-related inquiries and with cost-effective medicines.
IBD (Ulcerative Colitis and Crohn’s Disease) Treatment Market by Region
Based on the region, the global IBD (ulcerative colitis and Crohn’s disease) treatment market is segmented into North America, Europe, Asia Pacific, Latin America, and the Middle East & Africa.
North America accounted for the largest revenue share of the global IBD (ulcerative colitis and Crohn’s disease) treatment market in 2022. The increase in the availability of drugs for the treatment of ulcerative colitis and Crohn’s disease, as well as advantageous reimbursement policies and the rise in the prevalence of these diseases in the United States and Canada, are driving the market development in North America. The National Center for Biotechnology Information projects that by 2021, more than 0.75% of Canadians will have inflammatory bowel disease. Additionally, regionally improved reimbursement practices, high treatment rates, and a rise in prescriptions of innovative treatments are aiding regional expansion. The continued development of innovative treatments and supporting government policies are also expected to fuel the region’s revenue growth. For instance, the Crohn’s & Colitis Foundation is one of the important groups supporting numerous clinical and translational studies to identify treatments for colitis and Crohn’s disease.
Europe is anticipated to account for the second-largest revenue share in the global market during the forecast period. The rising number of people in the region receiving treatment for the disease is one of the main factors fueling industry expansion. Due to lifestyle changes, the rising incidence of smoking, and the corresponding rising prevalence of inflammatory bowel syndrome, the Middle East & Africa market will continue to grow at a revenue CAGR over the projection period. Additionally, more people are seeking treatment for these ailments, fueling market revenue growth in the region.
IBD (Ulcerative Colitis and Crohn’s Disease) Treatment Market Competitive Landscape
The market is highly concentrated, with many significant businesses controlling a sizable portion. With a broad portfolio of biologic medications for treating ulcerative colitis and Crohn’s disease, market leaders have gained a commanding position. The corporation has emerged as a prominent participant on the global stage thanks to successful penetration across key geographies. The dominance of these leading market players is supported by their new product launches and mergers and acquisitions.
Notable market participants include:
IBD (Ulcerative Colitis and Crohn’s Disease) Treatment Market Strategic Developments
North America is the key revenue growth region in the global IBD (ulcerative colitis and Crohn’s disease) treatment market.
The rising prevalence of IBD (ulcerative colitis and Crohn’s disease) globally and growing awareness of the potential threats of IBD are the prime market revenue-driving factors.
The TNF inhibitors segment accounts for the largest revenue share in the global IBD (ulcerative colitis and Crohn’s disease) treatment market.
The global IBD (ulcerative colitis and Crohn’s disease) treatment market is expected to register a revenue CAGR of 5.8% during the forecast period.
Key companies operating the global IBD (ulcerative colitis and Crohn’s disease) treatment market are AbbVie Inc, Takeda Pharmaceutical Company Limited, Pfizer Inc, Biogen, and Novartis AG.
*Insights on financial performance are subject to the availability of information in the public domain